Powered by

Aurora Bio, Inc Announces Clinical Data on Lead Program, AUR01, a Novel Systemic Amyloidosis Imaging Tracer, at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition; Analysis of PET images indicated uptake of AUR01 (124I-p5+14) i

Dec 08, 2019 - Business Wire

Aurora Bio, Inc www.Aurorabioinc.com today announced data for the company's novel PET radiotracer, AUR01, in development for systemic amyloidosis, was presented by Dr. Jonathan Wall, at ASH2019, in Orlando, FL.

Spencer Guthrie, Chief Executive Officer, stated, "We are very excited about the results presented today on 1st 18 patients scanned with the investigational radiotracer, AUR01. We were excited to detect multiple organs in AL, ATTR and ALECT2 patients, and particularly asymptomatic o...